Document Detail


Oral pilocarpine (5mg t.i.d.) used for xerostomia causes adverse effects in Japanese.
MedLine Citation:
PMID:  18635328     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To evaluate Japanese tolerability to pilocarpine of 5 mg t.i.d. METHODS: From January 2006 to July 2006, 39 patients with xerostomia received 5 mg t.i.d. pilocarpine for at least for 12 weeks unless they had experienced unacceptable adverse effects. All patients received radiotherapy that included the parotid glands in the radiation field >50 Gy. The body weights of the patients ranged from 42 to 73 kg (median 60 kg). RESULTS: Thirty-six of the 39 patients were evaluable. The tolerated rate was only 47%. Of the 25 patients whose body weights were less than 65 kg, the tolerated rate was 36%, whereas the rate of the 11 patients whose body weights were 65 kg or above was 72% (p=0.050). The most common adverse effect was sweating with an incidence of 64%. Response rate, which was defined as the total number of patients with an increase of at least 25 mm from the baseline in the VAS score divided by the number of maintaining patients among those who started pilocarpine after more than 4 months from the start of radiotherapy, was 40% at 12 weeks (n=15). CONCLUSION: For Japanese, 5mg t.i.d. pilocarpine caused a high incidence of unacceptable adverse effects. A lower dose of pilocarpine needs to be considered.
Authors:
Naoki Nakamura; Nakashi Sasano; Hideomi Yamashita; Hiroshi Igaki; Kenshiro Shiraishi; Atsuro Terahara; Takahiro Asakage; Kazunari Nakao; Yasuhiro Ebihara; Kuni Ohtomo; Keiichi Nakagawa
Publication Detail:
Type:  Journal Article     Date:  2008-07-16
Journal Detail:
Title:  Auris, nasus, larynx     Volume:  36     ISSN:  1879-1476     ISO Abbreviation:  Auris Nasus Larynx     Publication Date:  2009 Jun 
Date Detail:
Created Date:  2009-04-27     Completed Date:  2009-08-26     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7708170     Medline TA:  Auris Nasus Larynx     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  310-3     Citation Subset:  IM    
Affiliation:
Department of Radiology, Tokyo University Hospital, Tokyo, Japan. nnakamur-tky@umin.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Body Weight
Carcinoma / radiotherapy
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Head and Neck Neoplasms / radiotherapy
Humans
Male
Middle Aged
Muscarinic Agonists / adverse effects*,  therapeutic use
Parotid Gland / radiation effects
Pilocarpine / adverse effects*,  therapeutic use
Radiotherapy / adverse effects
Radiotherapy Dosage
Salivary Gland Diseases / chemically induced*,  diagnosis,  physiopathology
Severity of Illness Index
Xerostomia / drug therapy*,  etiology
Chemical
Reg. No./Substance:
0/Muscarinic Agonists; 92-13-7/Pilocarpine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Decompression effects of erythritol on endolymphatic hydrops.
Next Document:  A comparison of rapid-scanning X-ray fluorescence mapping and magnetic resonance imaging to localize...